Hematologic Malignancy
T Lymphoblastic Lymphoma
CI-CAN-00004058Explore in graph →
Hematologic11 active trials
- NCIt
- C6919
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004058Explore in graph →
Clinical trials
26 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 |
| Nov 14, 2018 |
| clinicaltrials |
Data updated 23 days agoSource updated May 17, 2024source: clinicaltrials